A 5-year Longitudinal Observational Study of Patients Undergoing
Therapy for IMISC (TARGET-DERM)
Recruitment Status: Recruiting
Estimated Study Completion Date: December 31, 2026
HS Connect listed this: October 2020
Sponsor: Target PharmaSolutions, Inc.
Information provided by (Responsible Party): Target PharmaSolutions, Inc.
TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Please link for complete trial details:
Multiple US locations. Please see link provided above for all location details and to confirm your location is recruiting.
Contact: Laura Dalfonso Phone: 9842340268
Laura Malahias Phone: 9842340268 ext 209